OncoSolid™ Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Services

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Organoid: Preclinical 3D Model

Organoids have emerged as a physiologically relevant in vitro model for developing cancer treatments. With advanced technologies and experienced researchers, Creative Biolabs can design and operate a full range of CAR-T efficacy assays using tumor organoids.

Tumor organoids are in vitro tridimensional assemblies of heterogeneous cell types of patient tumors, mimicking the structure and function of tissue or organ. Patient-derived organoids (PDOs) are proper models for CAR-T efficacy tests because they showed the most similarity of histopathological, gene mutant, and phenotypic characteristics to original tumors. Besides the improved clinical relevance of organoids, they are easier to manipulate than in vivo models.

Fig.1 Generation of cancer organoids and following application in cancer medicine. (Turhan, et al., 2021)

CAR-T In Vitro Efficacy Service at Creative Biolabs

Creative Biolabs provides well-characterized organoids derived from human tumors, mouse tumors, or pluripotent stem cells to investigate CAR-T efficacy and predict responses in patients.

Workflow

We provide end-to-end service on CAR-T efficacy tests using cancer organoids, from organoids establishment, and CAR-T construction, to evaluation of T cell function.

Fig.2 Illustration of CAR-T in vitro efficacy test service using cancer organoids. (Creative Biolabs)

Organoid Types

At Creative Biolabs, most organoids are established from 3 pathways.

Name	Description
Patient-derived Cancer Organoids	Organoids derived from patient biopsies and resection tumor tissue.
Human Pluripotent Stem Cells (hPSCs) Derived Organoids	PSCs cultured in a medium with growth factors can differentiate toward functional tissue and model tumorigenicity by genome editing.
Mouse Tumor Derived Organoids	Generate organoids from tumor tissue isolated from genetically engineered mice or xenograft mice.

Available Culture Methods

Organoids can be established using multiple cutting-edge techniques and methods with special application advantages.

Method	Culture system	Advantages	Limitation
Matrigel- based Method		Common, effective, and convenient	Only contains cancer cells; other cells can be added to the culture system to model the tumor microenvironment
Air-liquid Interface (ALI) Method		Mesenchymal/stromal cells and immune cells are preserved and combined to develop organoids	The number of immune cells decreased with a prolonged culture period
Microfluidic Method		Mimic the natural process of tumorigenesis in vivo; retain the cellular heterogeneity and structure of tumor tissue	Require advanced equipment; the number of immune cells decreased with a prolonged culture period

Well-characterized Cancer Organoid Models

We thoroughly validate formed organoids on similarity with the initial tumor.

Item	Technique	Function
Histological Features	Haematoxylin and eosin staining Immunofluorescent analysis	Histological organization analysis Cell identification
Genomic Features	Whole exome sequencing Whole genome sequencing Transcriptom sequencing	Somatic mutation profile Copy number variant (CNV) in whole genome Exonic single nucleotide variants (SNV) analysis

Multiple Types of Cancer Organoids

Creative Biolabs provides a living biobank of organoids with multiple human cancers.

Available Organoid Models of Various Cancers
Breast Cancer	Esophageal Carcinoma	Mesothelioma	Peritoneal Metastatic Colorectal Cancer
Brain Cancer	Fallopian Tube Carcinoma	Melanoma	Prostate Cancer
Bladder Cancer	Head and Neck Cancer	Nasopharyngeal Cancer	Pancreatic Cancer
Cervical Cancer	Kidney Cancer	Neuroendocrine Cancer	Sarcoma
Colon Cancer	Liver Cancer	Osteosarcoma
Gastric Cancer	Lung Cancer	Ovarian Cancer

Cancer Organoid Models-based CAR-T Efficacy Test Services

Organoids are used to investigate the therapeutic functions of CAR-T by co-culturing cancer organoids with targeted CAR-T cells. We provide multiple methods and ways to examine CAR-T mediated specific killing against cancer organoids and measure cancer organoids alterations after incubation.

Methods	Description	Detailed Information
Image analysis	Brightfield image of morphology changes.	Deformation and cell lysis
Immunostaining	Monitor organoids apoptosis, CAR-T cell invasion, and proliferation.	Staining with DAPI, CD3, CD8, Granzyme B, CC3, tumor marker, KI67, and so on.
Cytotoxicity	Measure the T cell-mediated target organoid lysis.	LDH release, flow cytometry analysis
ELISA	Detection cytokines released from organoids	IL-2, IFN‐γ and TNF‐α

Highlights

Large biobanks of organoids represent population diversity and cellular heterogeneity,
A high-throughput platform allows multiple cells and organoids combinations measurement simultaneously,
Normal organoids are provided to test off-target effects,
Cancer organoids can be engineered to express antigen protein and fluorescent protein.

Creative Biolabs is committed to developing potential gene and cell products for cancer treatment. We provide advanced cancer organoids for preclinical CAR-T efficacy tests at a competitive price. If you are interested in our service, please contact us for more detailed information.

References

Gunti, Sreenivasulu.; et al. Organoid and Spheroid Tumor Models: Techniques and Applications. Cancers. 2021, 13: 874.
Turhan, Ali G.; et al. iPSC-Derived Organoids as Therapeutic Models in Regenerative Medicine and Oncology. Frontiers in medicinevol. 2021, 8: 728543.
Richiardone, E.; et al. Metabolic Studies in Organoids: Current Applications, Opportunities and Challenges. Organoids. 2022, 1: 85-105.